|SCHEME PERFORMANCE SUMMARY|
|NAV as on Oct 31, 2019: Rs 35.0435|
|Performance of Nippon India Large Cap Fund as on 31/10/2019|
|Particulars||1 Year CAGR %||3 Year CAGR %||5 Year CAGR %||Since Inception|
|Nippon India Large Cap Fund||9.31||10.80||9.28||10.79|
|B: S&P BSE 100 TRI||14.02||11.79||8.87||9.67|
|AB: S&P BSE Sensex TRI||17.97||14.18||8.99||9.71|
|Value of Rs 10000 Invested|
|Nippon India Large Cap Fund||10,931||13,613||15,585||35,044|
|B: S&P BSE 100 TRI||11,402||13,984||15,296||30,954|
|AB: S&P BSE Sensex TRI||11,797||14,903||15,380||31,079|
|Inception Date: August 8, 2007|
|Fund Manager: Sailesh Raj Bhan (Since Aug 2007)|
|B - Benchmark | AB - Additional Benchmark | TRI - Total Return Index|
Note:: Different plans shall have a different expense structure. The performance details provided herein are of Growth Plan (Regular Plan).
|PERFORMANCE OF OTHER OPEN ENDED SCHEMES MANAGED BY FUND MANAGER: Sailesh Raj Bhan|
|Scheme Name/s||CAGR %|
|1 Year Return||3 Years Return||5 Years Return|
|Nippon India Pharma Fund||-4.71||-9.49||0.17||-6.24||4.06||-1.04|
|Nippon India Consumption Fund||18.46||13.98||4.10||11.64||6.89||10.49|
|Nippon India Multi Cap Fund||9.21||12.23||8.62||10.41||6.84||9.10|
Different plans shall have a different expense structure. The performance details provided herein are of Growth Plan (Regular Plan).
Mr. Sailesh Raj Bhan has been managing Nippon India Pharma Fund since Jun 2004.
Mr. Sailesh Raj Bhan has been managing Nippon India Consumption Fund since Sep 2004 & jointly with Ms Jahnvee Shah (Co-Fund Manager) since May 25, 2018.
Mr. Sailesh Raj Bhan has been managing Nippon India Multi Cap Fund since Mar 2005Note:
a.Mr. Sailesh Raj Bhan manages 4 open-ended schemes of Nippon India Mutual Fund. .
b. In case the number of schemes managed by a fund manager is more than six, in the performance data of other schemes, the top 3 and bottom 3 schemes managed by fund manager has been provided herein.
c. Period for which scheme’s performance has been provided is computed basis last day of the month-end preceding the date of advertisement.
d. Different plans shall have a different expense structure. The performance details provided herein are of Growth Plan (Regular Plan)..Note: Performance as on 31st October, 2019
B: Benchmark, AB: Additional Benchmark, TRI: Total Return Index
Past performance may or may not be sustained in future and the same may not necessarily provide the basis for comparison with other investment. Performance of the schemes (wherever provided) are calculated basis CAGR for the past 1 year, 3 years, 5 years and since inception. In case, the start/end date of the concerned period is non-business day (NBD), the NAV of the previous date is considered for computation of returns. Schemes which have not completed one year, performance details for the same are not provided. Performance details of closed ended schemes are not provided since these are not comparable with other schemes. TRI - Total Returns Index reflects the returns on the index arising from (a) constituent stock price movements and (b) dividend receipts from constituent index stocks, thereby showing a true picture of returns. In the perf ormance of other open ended schemes managed by the fund managers, the performance of the equity schemes is benchmarked to the Total Return variant of the Index. .
|Name of Scheme||This product is suitable for investors who are seeking*:|
|Nippon India Large Cap Fund
(An open ended equity scheme predominantly investing in large cap stocks)
• Long term capital growth
• Investment predominantly into equity and equity related instruments of large cap companies.
|Nippon India Consumption Fund
(formerly known as Nippon India Media & Entertainment Fund)
(An Open Ended Equity Scheme following consumption theme)
• long term capital growth
• Investment in equity, equity related securities of companies that are likely to benefit directly or indirectly from domestic consumption led demand.
|Nippon India Pharma Fund
(An open ended equity scheme investing in Pharma sector)
• long term capital growth
• investment in equity and equity related Securities of pharma & other associated companies
|Nippon India Multi Cap Fund
(Formerly, Nippon India Equity Opportunities Fund)
(Multi Cap Fund -An open ended equity scheme investing across large cap, mid cap,small cap stocks)
• long term capital growth
• Investment in equity and equity related securities.
|*Investors should consult their financial advisers if in doubt about whether the product is suitable for them|
The information contained herein is only for the reading/understanding and the views being expressed only constitute opinions and therefore cannot be considered as guidelines, recommendations or as a professional guide for the readers. Before making any investments, the readers are advised to seek independent professional advice, verify the contents in order to arrive at an informed investment decision. None of the Sponsor, the Investment Manager, the Trustee, their respective directors, employees, affiliates or representatives shall be liable in any way for any direct, indirect, special, incidental, consequential, punitive or exemplary damages, including on account of lost profits arising from the information contained in this material.